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BehaviorAkihisa T. Kodama,1 Chin-Chang Kuo,1 Thomas Boatwright,1 and Michael Dennin1,*
1Department of Physics & Astronomy, University of California, Irvine, CaliforniaABSTRACT We study the impact of the addition of particles of a range of sizes on the phase transition behavior of lung
surfactant under compression. Charged particles ranging from micro- to nanoscale are deposited on lung surfactant films in
a Langmuir trough. Surface area versus surface pressure isotherms and fluorescent microscope observations are utilized
to determine changes in the phase transition behavior. We find that the deposition of particles close to 20 nm in diameter signif-
icantly impacts the coexistence of the liquid-condensed phase and liquid-expanded phase. This includesmorphological changes
of the liquid-condensed domains and the elimination of the squeeze-out phase in isotherms. Finally, a drastic increase of the
domain fraction of the liquid-condensed phase can be observed for the deposition of 20-nm particles. As the particle size is
increased, we observe a return to normal phase behavior. The net result is the observation of a critical particle size that may
impact the functionality of the lung surfactant during respiration.INTRODUCTIONThe process of respiration is of vital importance to sustain
life in most land-based animals. In humans, gas exchange
occurs through the alveoli in the lungs and is fundamentally
a dynamic process. The alveoli expand and compress during
inhaling and exhaling, and the surface is covered by water-
based alveolar fluid. To protect the alveoli from completely
emptying of air and filling with fluid, surfactant films, pro-
duced by the alveolar cells, minimize surface tension of
the alveolar fluid-air interface. In addition, the reduction
of surface tension by the lung surfactant minimizes the
work required for breathing (1–3). A lack of lung surfactant
can have adverse effects on our health. A common instance
is with premature infants. They may develop a condition
known as neonatal respiratory distress syndrome (NRDS),
which is characterized by insufficient production of lung
surfactant from their alveolar cells. Administering replace-
ment surfactant to the infant has greatly reduced the
mortality rate from NRDS (4). Therefore, understanding
interaction of the lung surfactant layer under compression
and expansion is important for a full understanding of the
lung function.
A relatively good model system for studying dynamics
of lung surfactant is the surfactant films at the air-water
interface in a Langmuir trough. Surfactant films consist of
layers of molecules with a hydrophilic head and hydropho-
bic tail (5). Lung surfactant is composed of several different
components (3). Its main constituent is an amphiphilic phos-
pholipid known as DPPC (dipalmitoylphosphatidylcholine)Submitted January 29, 2014, and accepted for publication August 6, 2014.
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0006-3495/14/10/1573/9 $2.00(1,3,6). This saturated phospholipid allows the lung surfac-
tant to reach a high surface pressure and stabilize the alveoli
at the end of expiration. The remaining lipids are mainly
unsaturated, such as POPC (phosphatidylcholine), POPG
(phosphatidylglycerol), and POPI (phosphatidylinositol).
Other important components of lung surfactant include
several associated surfactant proteins (SP). In previous
works, the associated proteins are shown to be related to
the mechanical properties of the lung surfactant (6–18).
SP-B aids surfactant films folding by enhancing flexibility
while preventing material loss to the subphase. On the other
hand, SP-C is responsible for maintaining the fluidity of the
surfactant films and separating areas of solid-phase lipids
up to films collapse (7). This combination of molecules
and proteins maintains the functionality of lung surfactant
in the alveoli.
During the compression of the surface area, pulmonary
surfactant is known to go through several phases. One gen-
eral method to study the phase transition is via surface area
versus surface pressure isotherm measurements (1,2,5,19).
In its expanded state, the surfactants form a liquid-expanded
phase. In this state, the tails of the molecules are disordered
and associate to each other instead of contacting with
the water surface. With further compression, the isotherm
exhibits a coexistence between the liquid-expanded (LE)
and liquid-condensed (LC) phases. In the LC phase, the tails
of the molecules interact with each other and align such that
they point in the same direction. Moreover, at ~40 mN/m
of the surface pressure, the coexistence phase signifies
a plateau behavior. The plateau is also known as the
squeeze-out plateau because unsaturated lipids in Survanta
(Abbvie, North Chicago, IL) forms reservoirs and multi-
layer structures under the interface (6,10,20). By furtherhttp://dx.doi.org/10.1016/j.bpj.2014.08.010
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phase becomes more prevalent. At ~68 mN/m of the surface
pressure, the lung surfactant reaches the collapse region
(2,21–24). A giant fold phenomenon can be observed in
this system (1,7). A significant question is how this phase
behavior is impacted by the presence of particulate matter.
Particulate matter can result from a variety of sources
including dust, pollen, pollution, and dander. The impact
of particles into the biological systems depends on diverse
properties such as materials, surface conditions, particle
sizes, surface area, and particle shapes (25–31). The effect
of the deposition of nanoparticles on the Langmuir films
has been studied in various systems, including phospholipid
monolayers, lung surfactant, and model lung surfactant
(32–40). In particular, ultrafine particles with diameters
<100 nm can be transported to the alveoli (39,41,42). It
has been shown that the addition of 15 nm gold particles
drastically reduced the surface activity of the system (39).
Studies indicate that a majority of particles remain on the
alveolar surface after 24 h (43–45).
This can cause a buildup of fine particulate matter in the
lung surfactant of people who live or work in heavily
polluted areas andmay have an advanced impact on the func-
tionality of the alveoli (46). One potential consequence of
these particles is a disruption of the phase behavior. Further,
the interaction between the negatively charged carboxylate-
modified microspheres with a particle size of 200 nm and
monolayers of DPPC has been studied. This work shows
that the deposition of particles affects the isotherm behavior
by increasing the hysteresis area between the compression
and expansion cycles (37). In addition, hydrophobic polyor-
ganosiloxane nanoparticles with sizes of 136 and 12 nmwere
studied in phospholipid films with the addition of SPs. This
work shows that the size of nanoparticles is a critical factor
responsible for causing severe structural and functional dam-
age to the model lung surfactant films (40). Further, signifi-
cant amounts of nanoparticles are retained at the interface
and are released slowly into the aqueous subphase during
compression and expansion cycles (47). Thus, understanding
how particles of different sizes impact phase transitions in
surfactant layers is an important issue.
In this article we investigate the impact of particle size on
the phase behavior of the lung surfactant. We focus on parti-
cles in the range from 1.0 mm to 20 nm. The rest of the article
is organized into several sections. Materials and Methods
outlines the experimental details and the procedures for theTABLE 1 The actual particle size, particle charge, specific surface
polystyrene microspheres
Nominal particle size 1.0 mm 0.5 mm
Average actual size 1.1 mm 0.49 mm
Charge (milliequivalents/g) 0.0175 0.315
Specific surface area (cm2/g) 5.2  104 1.2  105
Charge density (milliequivalents/cm2) 3.4  107 2.6  106
Specific surface areas for 30-nm particles are estimated by average actual sizes
Biophysical Journal 107(7) 1573–1581preparation of the surfactant films and particle solutions. In
addition, we illustrate the experimental results for the sur-
face area versus surface pressure isotherm measurements
with the accompanied fluorescent microscope observation.
In the Discussion, we propose a potential schematic for the
impact of the particle size effect to the phase transition
behavior in the lung surfactant system.MATERIALS AND METHODS
We use Survanta (Abbvie) purchased from Abbott Nutrition (Columbus,
OH) to produce lung surfactant films. The product Survanta (generic
name: beractant) is bovine lung surfactant that is clinically used to treat
premature infants with NRDS (2). Compared to the lavaged calf-lung
surfactant, Survanta has fewer surfactant proteins (i.e., decreased SP-B)
due to the extraction of hydrophobic solvents performed during commercial
processing. The initial concentration of phospholipids in Survanta is
25 mg/mL. To ensure the even distribution of the Survanta films, we dilute
the concentration of phospholipids in Survanta to 1 mg/mL with a prepared
buffer solution without additional purification. This gives a DPPC concen-
tration of ~1.16  103 M. The same buffer solution is used as the aqueous
subphase for all the experiments (2). The water used in the buffer solution
is filtered through a Milli-Q system (Millipore, Billerica, MA) with a
measured resistivity of 18.2 MU. The buffer solution is composed of
150mMNaCl, 5.0mMCaCl, and 0.2mMNaHCO3.We ensure the pH value
of the buffer solution is between 6.9 and 7.3 before conducting experiments.
Microspheres are spherical particles formed from an amorphous poly-
mer. The carboxylate-modified microspheres create a charged surface
around the particles. In our experiments, we use microspheres made by
polystyrene, which has the density of 1.055 g/cm3. Different sizes of red
fluorescent carboxylate-modified polystyrene microspheres are obtained
from Invitrogen (Carlsbad, CA). The nominal particle diameters are 1.0,
0.5, and 0.1 mm, and 40 and 20 nm. Additional particles of 30 nm are
obtained from Sigma-Aldrich (St. Louis, MO). The details of the actual
particle size, particle charge, specific surface area, and surface charge
density are exhibited in Table 1. All particle solutions are diluted to
1% solids by the addition of Milli-Q water (Millipore) to the original solu-
tion. The particle solutions are sonicated thoroughly before conducting
experiments. A fluorescent tag of NBD C12-HPC (1-palmitoyl-2-[12[(7-
nitro-2-1, 3-benzoxadiazol-4-yl) amino] dodecanoyl]-sn-glycero-3-phos-
phocholine) obtained from Avanti Polar Lipids (Alabaster, AL) is used to
visualize the domain structure during phase coexistence. The fluorescent
tag powder is dissolved in a 3:1 chloroform-methanol solution such that
the final concentration of the fluorescent tag is 0.1 mg/mL.
Two experimental methods are utilized to study the lung surfactant films
with the deposition of nanoparticles:Method 1
Our initial studies used standard methods of putting the florescent tag
directly into the aqueous mixture of Survanta solution so that the tag and
Survanta are placed on the water surface simultaneously. Using thisarea, and surface charge density of carboxylate-modified
0.1 mm 40 nm 30 nm 20 nm
0.109 mm 0.045 mm 0.032 mm 0.024 mm
0.3092 0.725 0.07 0.7512
5.2  105 1.3  106 1.8  106 2.4  106
5.9  107 5.6  107 3.9  108 3.1  107
.
Particles on Pulmonary Surfactant 1575method, we observe bright dots on the surface at the surface pressure of
z40–45 mN/m, consistent with previous studies. However, these structures
inhibit the quantitative analysis of the domain structure. In addition, for our
studies, we utilize a number of compression and expansion cycles before
the cycles of interest for measurement in order to fully relax the system.
In this case, we find that the intensity of the florescence significantly de-
cays. Therefore, to clearly observe the domain structure, a slightly different
procedure is utilized to observe and record the images of the lung surfactant
films. After two cycles of compression and expansion, 15 mL of the tag
solution is deposited on the surface by the same method with the deposition
of lung surfactant and particles solutions. At this point, the experiment is
conducted in the dark room to preserve the fluorescence of the tag. Another
15 min elapsed before an additional compression and expansion cycle
is applied to ensure the even distribution of the fluorescent tag. The
images of the fourth compression cycle are observed and recorded at
different surface pressures. We do not find any significant difference in
the isotherm measurement with or without the presence of fluorescent tag
solution. The ratio between the LC and LE phase is measured by the ratio
of the binary image processed by a MATLAB program (The MathWorks,
Natick, MA).FIGURE 1 Isotherm of pure lung surfactant over five compression and
expansion cycles. (Solid arrows) Progression isotherm measurements
from the first to the fifth cycle. (Dashed arrows) Directions of compression
and expansion. Several phase transitions occur under compression. The LE
to LC-LE coexistence transition corresponds to the observed change in
slope ~15 mN/m. Under further compression, the squeeze-out plateau is
observed when the surface pressure is ~42 mN/m. At the surface pressure
of ~65 mN/m, we observe an LC phase collapse. An elastic stretching is
observed at the surface pressure of ~37 mN/m under expansion.Method 2
Surface area versus surface pressure isotherms at constant temperature are
measured in a Langmuir trough (Nima model No. 102M; Biolin Scientific,
Stockholm, Sweden). The surface pressure is measured by a tensiometer via
the standard Wilhelmy method. The compression of the surface area is from
79.0 to 18.0 cm2 with a compression speed of 15 cm2/s. The temperature of
the aqueous subphase is controlled to be 37C by a water-cycling heating
system. To conduct the measurement, we fill the Langmuir trough with
50-mL buffer solution. Then we deposit 150 mL of the Survanta solution
by evenly contacting and extracting droplets of the solution from the tip
of a syringe on the liquid surface. We wait for 15 min to allow the surfactant
to spread homogeneously over the surface. Afterwards, particles are depos-
ited in a similar process as used for the surfactant with another 15-min
pause before the measurement of five compression and expansion cycles.
The domain structure and deposited particles are observed by a fluorescence
microscope (model No. BX60MF5; Olympus, Melville, NY) with a charge-
coupled device camera.RESULTS
Surface pressure versus surface area isotherms
A typical isotherm measurement of pure lung surfactant un-
der compression and expansion for five cycles is shown in
Fig. 1. The Survanta is deposited at the air-liquid interface
by the process described in Materials and Methods. The sur-
face area versus surface pressure isotherm of pure lung sur-
factant is measured at 37C, which is approximately normal
physiological temperature. Several different phases of lung
surfactant are observed in the measurement. Starting from
a surface pressure of z15 mN/m, a small increase of the
surface pressure under compression can be observed. As
the surface area decreases, the slope of the isotherm be-
comes steeper, indicating the onset of LC phase formation.
Due to the multicomponent surfactant, it is standard to only
see the change in slope (2). This is in contrast to the pure
DPPC system in which one observes a plateau during the
LC/LE coexistence. With further compression, a plateau
region is reached, which is associated with the monolayer-to-multilayer transition that is controlled by the surfactant
proteins (i.e., the squeeze-out plateau) (6,10). Upon further
compression, the increase of the isotherm slope corresponds
to the LC phase dominating the lung-surfactant films.
Beyond a surface pressure of 65–68 mN/m, the film col-
lapses, and the formation of giant folds occurs on the surface
(1,7). Under expansion, the isotherms show a drastic
decrease of the surface pressure followed by a slight elastic
stretch when the surface pressure is ~37 mN/m. This elastic-
stretch behavior is related to the recovery of films from its
collapse and folding at the high surface pressure (49).
Consecutive compression and expansion cycles are indi-
cated as arrows in Fig. 1. A significant shift between the first
and second compressions exhibits a large amount of mate-
rial loss from the surface when the film collapses during
the first compression. Furthermore, consistent shifts of the
isotherms can be observed in the stabilized surfactant films
after the first compression. The phase behavior is identical
across the multiple compression and expansion cycles.
We utilized the isothermmeasurements of the lung surfac-
tant with the deposition of particles to study the impact of
particles size on the phase behavior. We apply five compres-
sion and expansion cycles to the surfactant films and the
comparison of the isotherms for the particles measuring
(a) 20 nm, (b) 40 nm, and (c) 0.5 mm, as shown in Fig. 2.
The arrows in the figures indicate the order of the isotherm
shift from the first to fifth compression and expansion cycles.
For all particle sizes, the first compression illustrates phase
behavior similar to the pure lung surfactant. At the thirdBiophysical Journal 107(7) 1573–1581
FIGURE 2 The surface pressure versus the surface area isotherm mea-
surements of the lung surfactant with various sizes of particles. Three
different sizes of particles of (a) 20 nm, (b) 40 nm, and (c) 0.5 mm are shown
for five consecutive compression and expansion cycles. (Solid arrows)
Biophysical Journal 107(7) 1573–1581
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presence of 20-nm particles. Themost dramatic feature is the
loss of the squeeze-out plateau. Instead, a constant increase
in the slope of the surface pressure from the LE-LC coexis-
tence phase to the LC phase under the compression is
observed. This behavior is repeated in all further compres-
sion cycles. For all particle sizes>20 nm, we do not observe
the annihilation of the squeeze-out plateau. This indicates a
critical particle size close to 20 nm that impacts the phase
transition behavior of the lung surfactant.
With the deposition of 20-nm particles on the surfactant
films, the annihilation of the squeeze-out plateau occurs
with repeated compression cycles. We also vary the initial
concentrations of the 20-nm particle solutions. Fig. 3 a shows
the isothermsof the lung surfactantwith 20-nmparticles for 1,
0.5, and 0.33% solids on the fifth compression. Changes in the
horizontal shifts for each particle concentration are due to the
differences of the material loss in each individual measure-
ment. We observe that a significant annihilation of the
squeeze-out plateau occurs for the 1 and 0.5% solid solutions
on the fifth compression whereas the deposition of 0.33%
solid solution does not cause a significant difference. This
suggests that the effect requires a minimum number of parti-
cleswithin the critical size range to impact the phase behavior.
In addition, the isotherms of 20-, 30-, and 40-nm particle
solutions with 1% solid at the fifth cycle are exhibited in
Fig. 3 b. The phase behavior of the 30-nm particle is interme-
diate between the 20- and 40-nm particles, particularly
in terms of the size of the plateau as indicated by the arrow.
To determine the impact of the total surface area of the parti-
cles on the phase behavior, we use 20-, 40-, and 0.1-mm par-
ticle solutions with adjusted concentrations. Based on the
solid weight concentration of 20-nm particles solution, we
use two-times the 40-nm particles solution and five-times
the 0.1-mm particles solution to deposit a similar total-parti-
cle-surface area. The comparison between the surfactant films
with the adjusted amount of 20-nm, 40-nm, and 0.1-mm par-
ticles at the fifth compression is shown in Fig. 3 c. In both the
surfactant films with 40-nm and 0.1-mm particles, the plateau
exists regardless of the change of the depositing amounts.
This suggests that only the 20-nm particles interfere with
the phase transition of the lung surfactant.LC domain observation
Observations of the particle impact on domain morphology
using a fluorescence microscope are shown in Fig. 4. TheContinuous shifting of isotherms from the first to fifth cycles. (Dashed
arrows) Observed squeeze-out plateau. During the first compression, there
is no significant change for the phase behavior for the surfactant films with
deposited particles for all three sizes. After the third compression, the
squeeze-out plateau vanishes for the surfactant films with 20-nm particles;
whereas the surfactant films in the presence of other particle sizes behave
similarly to the pure lung surfactant without the deposition of particles.
FIGURE 3 The isotherm measurements of the lung surfactant with
different depositions of particles at the fifth cycle. (Dashed arrows)
Observed squeeze-out plateau. (a) The isotherms of lung surfactant with
FIGURE 4 The fluorescent microscope images of the lung surfactant
films with the deposition of particles at different surface pressure. The im-
ages of different particles are shown in panels a and d for 20 nm, panels b
and e for 40 nm, and panels c and f for pure lung surfactant. The deposition
volume is 50 mL for each particle size. The surface pressures for the images
are 34 mN/m for panels a–c and 42 mN/m for d–f. The scale bars in images
are 130 mm. A small ratio of the fluorescent tag is deposited on the lung
surfactant for the observation of the domain structure. (Bright and dark
regions) LC domain and LE liquid phase, respectively.
Particles on Pulmonary Surfactant 1577images are taken at surface pressures of 34 mN/m (Fig. 4, a–
c) and 42 mN/m (Fig. 4, d–f), which correspond to the obser-
vation of the LC-LE coexistence phase and the squeeze-out
plateau under compression. Two different particle sizes of
20 nm (Fig. 4, a and d) and 40 nm (Fig. 4, b and e) are
used as a comparison with the pure lung surfactant
(Fig. 4, c and f). The observation of the morphology changevarious amounts of the 20-nm particle solutions. We deposit three different
solid concentrations for the 20-nm particles solutions: 1% solid (black
solid), 0.5% solid (red dashed), and 0.33% solid (blue dotted). Only the
1% particles solution exhibits a complete removal of the squeeze-out
plateau on the fifth compression. This indicates a threshold for the particle
concentration necessary to cause the effect. (b) The isotherms of lung sur-
factant with different sizes of 1% solid particle solutions: 20 nm (black
solid), 30 nm (red dashed), and 40 nm (blue dotted). The isotherm of
30 nm is intermediate between the deposition of 20 nm and 40 nm particles.
(c) The isotherms of lung surfactant with different sizes and amounts of par-
ticles on the fifth compression and expansion cycle. In this case, the volume
of the solutions of 20 nm (black solid), 40 nm (red dashed), and 0.1 mm
(blue dotted) are adjusted to give similar total surface area of the particles.
The results show a significant particle size effect only for 20-nm particles,
indicating that total surface area of deposited particles is not relevant. To
see this figure in color, go online.
Biophysical Journal 107(7) 1573–1581
FIGURE 5 The normalized LC domain area fraction as a function of
surface pressure. The LC domain area fraction is defined by the ratio
between the LC area and the total surface area. The symbols in the plot
indicate pure lung surfactant (open black square), the lung surfactant
with the particles of 20 nm (solid black square), 40 nm (solid red circle),
0.1 mm (open red circle), and 0.5 mm (solid blue diamond). The surface
pressure ranges from 30 to 42 mN/m and the LC domain area fraction is
normalized to the fraction at the surface pressure of 30 mN/m. The deposi-
tion of 20-nm particles is seen to cause a rapid growth of the LC domain
compared to the other particle sizes and pure lung surfactant. To see this
figure in color, go online.
1578 Kodama et al.of DPPC domains in the LC phase has been utilized to study
various DPPC and lung surfactant systems (2,36–38,50–53).
In our experiment, we observe the previously reported
behavior that the LC solidlike domains appear on the
surface when it reaches the LC-LE coexistence phase
(Fig. 4 c). Further compression toward the liquid squeeze-
out plateau results in no significant change for the domain
structure (Fig. 4 f). This corresponds to the formation of
the reservoir underneath the LE phase. A slight difference
of the domain size in Fig. 4, c and f, is due to the strong
localized domain size fluctuation in different locations on
the surface.
For the deposition of 20- and 40-nm particles on the sur-
factant films, we observe two different behaviors. For 40-nm
particles, we find similar behavior to the pure lung surfac-
tant. The domain structure does not have any significant
change at the surface pressures of 34 and 42 mN/m
(Fig. 4, b and e). However, a significant change of the
domain structure can be observed with the deposition of
20-nm particles on the surfactant films. At a surface pressure
of 34 mN/m, solidlike LC domains occur that are similar to
the other cases (Fig. 4 a). When the surface pressure rises
toward 42 mN/m under compression, the LC domains
grow and start to coalesce to form a networklike structure
(Fig. 4 b). This indicates that the 20-nm particles are most
likely impacting the squeeze-out dynamics, but particles
of 40 nm or larger do not have a significant effect on this
process. This is consistent with the factor that only the depo-
sition of the 20-nm particles causes changes in isotherm
measurements.
We are able to quantify the impact on domain formation
by measuring the LC domain fraction as a function of the
surface pressure. Results for the different sizes of particles
are shown in Fig. 5. We focus on surface pressures
ranging from 30 to 42 mN/m to capture impact on the
squeeze-out phase. Each point corresponds to the average
of 10 random binary images processed to detect the LC
domain fraction. To compare the increase of the LC frac-
tion, we normalize the data to the value at the surface
pressure of 30 mN/m for each size particle to account
for background variation in fluorescence. The result shows
a gradual increase of the LC fraction, except for the sur-
factant films with 20-nm particles. In this case, the LC
domain fraction increases rapidly compared to the other
sizes, then plateaus when the normalized LC fraction is
close to 0.3. It remains relatively high until 46 mN/m,
where all the particle sizes show similar ratios. This result
shows a much quicker growth of the LC domain in the
absence of the squeeze-out plateau for the deposition of
20-nm particles.
To further examine the interaction between deposited par-
ticles and LC domains, we compare the images of the LC
domain to the deposited particles in the same area. The im-
ages of the LC domains and the fluorescent particles are
observed by fluorescence microscope with different opticalBiophysical Journal 107(7) 1573–1581filters for different absorption wave lengths of the fluores-
cent tag and fluorescent particles. In this observation, we
search for the topographic features that can be seen in
both channels to confirm the relative positions of LC do-
mains and deposited particles. The overlapping images for
the deposition of 20-nm particles and 0.5-mm particles are
shown in Fig. 6, a and b. The LC domains and deposited
particles correspond to the green- and red-scale images,
respectively. For the deposition of 20-nm particles, we
observe that the particles prefer to accumulate inside the
LC domain and at the domain boundaries. In contrast, for
the deposition of 0.5-mm particles, the domain–particle
interaction seems much weaker than the 20-nm particles
in which the particles do not show a strong preference to
specific locations. It is worth mentioning that we also
observe a uniform bright background for the deposition of
20-nm particles with the respective optical filter. This sug-
gests a background of 20-nm particles, which is independent
of the LC domain structure and the accumulating particle
clumps.DISCUSSION
From previous research, the formation and structure of the
squeeze-out phase provides a unique contribution to
the functionality of lung surfactant in respiration (6).
The molecules of the LE phase form reservoirs at the
FIGURE 6 Overlapping images of the domain structure and the depos-
ited fluorescent particles. We apply two optical filters to separate the signal
from the domain structure and the deposited particles. (Green scale images)
Domain structure; (red scale images) fluorescent particles. The scale bars in
images are 130 mm. To compare the domain-particle interaction under
compression, two particle sizes of (a) 20 nm and (b) 0.5 mm are observed
at the surface pressure of 34 mN/m. (Bright dots) Particles in the images.
The scale bars in the images are 130 mm. The relative positions are
confirmed by the topographic feature of the impurity particles. To see
this figure in color, go online.
Particles on Pulmonary Surfactant 1579squeeze-out plateau region, which provides a lower sur-
face tension under compression and a rapid recovery un-
der expansion (20). The elimination of the squeeze-out
plateau is an indication that the formation of reservoirs un-
derneath the LE phase region is prevented. Thus, the sur-
factant molecules are more likely to form larger LC
domains on the surface under compression. This is
confirmed by our observation of a rapid increase of the
LC domain fraction for case of 20-nm particles. Other
research for the lung surfactant at the interface of com-
pressed air bubbles has shown similar behavior. In that
case, particles close to 15 nm prevent proper respreading
of the layer, but no acknowledged mechanism has been
identified (39). Further study is needed to determine
whether the mechanism we have identified is relevant to
this experiment.
It is interesting to note the connection between our results
and previous work focusing on just two different particles
sizes and their effects on simplified lung surfactant systems
(40). In particular, this work and ours illustrates that oneneeds to consider not just particle size, but the system of
surfactants and the specific phase behavior being studied.
For example, the work in Dwivedi et al. (40) reports that
12-nm particles have little effect on the LC/LE phase
behavior of pure DPPC, whereas, 0.14-mm particles do
impact this phase behavior. When they consider a system
of DPPC, DPPG, and a single lung surfactant protein (SP-
C), sufficient concentration of 12-nm particles do reduce
the plateau. In addition, one interesting feature is that they
report sufficient quantities of 0.14 mm increase the plateau,
something we did not specifically observe. However, in our
studies of a completely different surfactant system, we have
shown that nanoparticles impact the collapse of that mono-
layer only for a specific size window (49). Therefore, com-
parisons using only a few particle sizes can be misleading if
the behavior of interest is due to a specific window of parti-
cle sizes, especially if the relevant window is dependent on
the details of the monolayer composition. Therefore, further
work with a greater variation in particle sizes and the same
surfactant systems would be needed for a detailed, quantita-
tive comparison of our observations and those reported in
Dwivedi et al. (40).
A general question is whether the surface condition of
particles, such as the surface charge density of particles
in our experiment, caused the impact to the isotherm
behaviors. It is certainly true that one expects surface
modifications to exist that will impact the phase behavior.
However, our focus is on particles with essentially the
same surface properties, so there is only some variation in
surface charge (Table 1). In particular, the behavior of the
30-nm particles represents a monotonic change in behavior
going from 20 to 40 nm (Fig. 3 b), but the correspond-
ing variation in surface charge density is not monotonic
(Table 1). This provides the most direct evidence that, for
these particles, the change in phase behavior is dominated
by the particle size and not the surface properties.
It is known that the total surface area of nanoparticles is
associated with the biological activity of the lung surfac-
tant system (25,26,54,55). Therefore, one possible explana-
tion of the observed particle size effect is a purely surface
area effect where the surfactant molecules coat the surface
of the deposited particles under compression and expan-
sion cycles. However, if this effect was dominant, the anni-
hilation of the squeeze-out plateau should be related to
total surface area of particles regardless of the particles’
sizes. Our isotherm and optical measurements confirm
that 20-nm particles eliminate the squeeze-out plateau of
the lung surfactant, whereas particles with the sizes
>40 nm do not have a significant effect. Further, our re-
sults in Fig. 3 c show that although the deposited particles
have similar total surface area, the effect only occurs with
the deposition of 20-nm particles. These results provide
strong evidence that total available surface area is not
responsible for the change in phase behavior of the lung
surfactant.Biophysical Journal 107(7) 1573–1581
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may impact the isotherm behavior:
1. We note that all of the particles exhibit some degree of
aggregation. These are the substantially brighter dots in
the images. The aggregates may be the controlling
element that interacts with the monolayer to disrupt the
phase behavior. To produce a size effect similar to
what we observe, this would require that the details of
the aggregation be size-dependent. This would essen-
tially be an indirect mechanism in which the particle
size produces aggregates that interact with the monolayer
in different ways. This could also be connected with a
surface area effect if the different size particles produce
aggregates with differentiated surface areas based on par-
ticle size. Further work would be required to identify the
mechanism by which aggregates disrupted the isotherm.
2. Another possibility is that particles of specific size
interact directly with specific molecular components of
the monolayer in a way that disrupts the squeeze-out
behavior. This mechanism is based on reports that the
formation of reservoirs in the squeeze-out phase is highly
correlated with the associated proteins in the lung surfac-
tant (8–12,14,15,18), and the lack of the surfactant pro-
teins directly enhances the irreversibility of the
surfactant films (7). Therefore, it is possible that the
deposited 20-nm particles alter the interaction between
surfactant proteins and phospholipids. The idea is similar
to the behavior observed for the case of hydrophobic, al-
kylated, gold 2-nm nanoparticles on Survanta. Work on
this system shows that particles accumulate with the pro-
teins in the LE phase around the LC domains (36). We
suggest a similar interaction in our system where a strong
interaction between the small carboxylate-modified
charged particles and the surfactant proteins comprises
the main factor in the particle-size effect.
It has been reported that the relative lengths of the surfac-
tant proteins are ~2 and 4 nm for hydrophobic SP-C and SP-
B, and 20 and 92 nm for hydrophilic SP-A and SP-D
(13,17,18). In particular, the initial formation of the reser-
voirs in the squeeze-out phase requires the presence of
SP-B and SP-C to interact with phospholipids (10). For
the larger-size particles, the proteins prefer to interact with
the surfactant films due to the relatively flat surface curva-
ture of the larger particles. It leads to the normal domain-
forming process similar to that for the pure lung surfactant.
On the other hand, when the particle sizes are sufficiently
small, the surfactant proteins tend to directly interact with
the deposited particles. It worth noting that the main
squeeze-out-related surfactant protein in Survanta is SP-C.
One possible interaction is that SP-C attaches to the
deposited particles by the positive charged N-terminal
segment, which is similar to the situation in which the sur-
factant proteins attach to the small phospholipids bilayer
reservoirs (10,56). This process consecutively decreasesBiophysical Journal 107(7) 1573–1581the active surfactant proteins in the surfactant films under
the compression and expansion cycles, which is consistent
with the factor that the elimination of the squeeze-out phase
gradually appears with the compression cycles. In addition,
it also enhances the irregular coalescence of the LC solid
phase under compression (7,20,53), resulting in the forma-
tion of the networklike LC domains. As with the particle
aggregate mechanism, additional work would be needed
to determine whether the small particles preferentially
interact with the components of the lung surfactant. Further-
more, it is also possible that the effects are a combination of
aggregates and individual particles impacting the phase
behavior.
In summary, we have provided the experimental evidence
for the particle size playing a key role in determining the
surfactant phase behavior. It remains an open question
whether or not this is a surface area effect driven by differ-
ential aggregation of particles or a particle-molecule inter-
action. Both scenarios are interesting, and the actual
mechanism may be a combination of these effects, or
another process completely. These issues will be the subject
of future studies with other techniques, such as utilizing a
single molecule fluorescent microscope to detect the inter-
action and using an atomic force microscope to study the
heterogeneous distribution of the LC domains.
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